Partner Jeff Fessler Joins Client ContraVir Pharmaceuticals, Inc. at NASDAQ Opening Bell Ringing
Press Release – New York, NY – March 22, 2016 – Sichenzia Ross Friedman Ference LLP partner Jeff Fessler joined representatives of client ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, at the NASDAQ MarketSite in Times Square to ring the March 21 closing bell.
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. The company’s common stock has traded on The Nasdaq Capital Market under the symbol “CTRV” since February 27, 2015.
- Two Bright Sides of Estate Planning During COVID-19 - July 1, 2020
- Sichenzia Ross Ference LLP Represents Aegis Capital in $5.4 Million Public Offering of Avinger, Inc. Common Stock - June 26, 2020
- Sichenzia Ross Ference LLP Represents Hudson Capital Inc. in $3.7 Million Registered Direct Offering - June 24, 2020